TPST Tempest Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TPST

Price (delayed)

$3.34

Market cap

$64.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$74.17M

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct ...

Highlights
The EPS has grown by 16% YoY and by 8% from the previous quarter
The net income has grown by 10% YoY and by 6% from the previous quarter
Tempest Therapeutics's debt has increased by 26% YoY but it has decreased by 2.2% from the previous quarter
The equity has plunged by 124% from the previous quarter and by 104% YoY
The quick ratio is down by 26% since the previous quarter and by 16% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.millendo.com
Peers: OMGA

Key stats

What are the main financial stats of TPST
Market
Shares outstanding
19.25M
Market cap
$64.29M
Enterprise value
$74.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$29.32M
EBITDA
-$27.21M
Free cash flow
-$28.18M
Per share
EPS
-$2.2
Free cash flow per share
-$2
Book value per share
-$0.09
Revenue per share
$0
TBVPS
$1.7
Balance sheet
Total assets
$23.99M
Total liabilities
$25.18M
Debt
$21.01M
Equity
-$1.19M
Working capital
$4.87M
Liquidity
Debt to equity
-17.65
Current ratio
1.66
Quick ratio
1.5
Net debt/EBITDA
-0.36
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-90.1%
Return on equity
-378.2%
Return on invested capital
-105.9%
Return on capital employed
-177%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TPST stock price

How has the Tempest Therapeutics stock price performed over time
Intraday
-10.7%
1 week
-20.29%
1 month
-20.85%
1 year
107.45%
YTD
190.43%
QTD
996.16%

Financial performance

How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.58M
Net income
-$31.11M
Gross margin
N/A
Net margin
N/A
The net income has grown by 10% YoY and by 6% from the previous quarter
The company's operating income rose by 7% YoY and by 7% QoQ

Growth

What is Tempest Therapeutics's growth rate over time

Valuation

What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 16% YoY and by 8% from the previous quarter
The equity has plunged by 124% from the previous quarter and by 104% YoY

Efficiency

How efficient is Tempest Therapeutics business performance
The company's return on assets has shrunk by 80% YoY and by 20% QoQ
The ROE has plunged by 73% from the previous quarter
TPST's return on invested capital is up by 47% year-on-year and by 18% since the previous quarter

Dividends

What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TPST.

Financial health

How did Tempest Therapeutics financials performed over time
The company's total assets is 4.7% lower than its total liabilities
The company's total assets has shrunk by 62% YoY and by 22% QoQ
The current ratio has declined by 34% year-on-year and by 23% since the previous quarter
The equity has plunged by 124% from the previous quarter and by 104% YoY
Tempest Therapeutics's debt has increased by 26% YoY but it has decreased by 2.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.